Neoral-Sandimmun (Ciclosporin)

Ciclosporin, the active ingredient in Neoral-Sandimmun, is a calcineurin inhibitor presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat severe psoriasis and rheumatoid arthritis in appropriate patients.

GNH USA supplies Neoral-Sandimmun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Neoral‑Sandimmun, a calcineurin inhibitor, is used in conditions where immune modulation is required.

Organ transplant rejection: prevents graft rejection and improves long‑term graft survival. Severe psoriasis: reduces skin inflammation and plaque formation. Rheumatoid arthritis: diminishes joint inflammation and disease progression.

Ciclosporin may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Headache: mild to moderate intensity. - Hypertension: elevated blood pressure requiring monitoring. - Hyperlipidaemia: increased cholesterol or triglycerides. - Nausea: gastrointestinal discomfort.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function, may be irreversible. - Severe infections: opportunistic bacterial, viral or fungal infections. - Malignancy: increased risk of lymphomas and skin cancers. - Hepatotoxicity: liver enzyme elevations or hepatitis. - Seizures: rare neurologic events.

Before initiating therapy, clinicians should assess baseline organ function and counsel patients on potential risks.

Monitor kidney function: perform regular serum creatinine and eGFR tests. Monitor blood pressure: check regularly and manage hypertension. Monitor lipid profile: assess cholesterol and triglycerides. Avoid live vaccines: immunosuppression may reduce vaccine efficacy. Store at room temperature: keep in the original container, protect from moisture and light.

Ciclosporin has several clinically important drug interactions that may require dose adjustment or avoidance.

Major Interactions (Avoid): - Ketoconazole: markedly increases ciclosporin plasma levels. - Rifampin: significantly reduces ciclosporin concentrations. - Carbamazepine: lowers ciclosporin exposure, risking therapeutic failure.

Moderate Interactions (Monitor Closely): - NSAIDs: may potentiate nephrotoxic effects. - Calcium channel blockers (e.g., diltiazem): can raise ciclosporin levels modestly.